CompanyGraph
Zylox-Tonbridge Medical Technology Co., Ltd.
2190 · HKEX · China
Price data from its 818 listing on FSX, quoted in EUR
zyloxtb.comFinancials as of FY2024–FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsLow earnings quality
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.17%
Annual Rate
HKD 0.25Paid annual
Payout Ratio
22.8%Sustainable
Payback Period
9.2 yr
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
8.24BHKD1.05B · vs all stocks (USD)
Trailing P/E
19.29xvs Medical Devices peers
Revenue (TTM)
1.41BHKD180.07M · vs all stocks (USD)
Profit Margin
25.25%vs Medical Devices peers
Beta
0.3070xvs all stocks
52-Week Change
-7.61%vs all stocks
Market Capitalization
8.24BHKD1.05B · vs all stocks (USD)
Enterprise Value
7.04BHKD897.42M · vs all stocks (USD)
Trailing P/E
19.29xvs Medical Devices peers
Forward P/E
13.13xvs Medical Devices peers
Price to Sales (TTM)
5.91xvs Medical Devices peers
Price to Book (MRQ)
2.06xvs Medical Devices peers
Enterprise to Revenue
4.98xvs Medical Devices peers
Enterprise to EBITDA
18.14xvs Medical Devices peers
Profit Margin
25.25%vs Medical Devices peers
Operating Margin
28.04%vs Medical Devices peers
Return on Assets (TTM)
5.13%vs Medical Devices peers
Return on Equity (TTM)
9.82%vs Medical Devices peers
Revenue (TTM)
1.41BHKD180.07M · vs all stocks (USD)
Revenue per Share (TTM)
3.79HKDUpdated Sep 26, 2026Quarterly Revenue Growth
31.10%vs Medical Devices peers
Gross Profit (TTM)
1.03BHKD131.77M · vs all stocks (USD)
EBITDA (TTM)
388.01MHKD49.46M · vs all stocks (USD)
Net Income (TTM)
356.63MHKD45.46M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
49.90%vs Medical Devices peers
Operating Cash Flow (TTM)
542.88MHKD69.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
135.14MHKD17.23M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2516HKDUpdated Sep 26, 2026Trailing Annual Dividend Yield
1.17%vs all stocks
Payout Ratio
22.75%vs Medical Devices peers
EPS (Basic)
0.7646CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7552CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
319.61MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
319.61MSharesFY2025 · Dec 31, 2025Operating Cash Flow
19.54MCNYFY2024 · Dec 31, 2024Free Cash Flow
-171.73MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
418.11MCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
100.26MCNYFY2024 · Dec 31, 2024Stock-based Compensation
23.74MCNYFY2024 · Dec 31, 2024Other Non-cash Items
-65.17MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-351.00KCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-38.93MCNYFY2024 · Dec 31, 2024Capital Expenditures
-191.26MCNYFY2024 · Dec 31, 2024Net Acquisitions
-1.10MCNYFY2024 · Dec 31, 2024Purchase of Investments
-1.39BCNYFY2024 · Dec 31, 2024Sale of Investments
772.02MCNYFY2024 · Dec 31, 2024Other Investing Activity
7.21MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-801.86MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-50.00MCNYFY2024 · Dec 31, 2024Net Short-term Debt Issuance
87.00MCNYFY2024 · Dec 31, 2024Common Stock Repurchase
-66.91MCNYFY2024 · Dec 31, 2024Other Financing Charges
-5.37MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
-35.22MCNYFY2024 · Dec 31, 2024Shares Outstanding
317.74MSharesUpdated Sep 26, 2026Float Shares
175.80MSharesUpdated Sep 26, 2026% Held by Insiders
48.01%vs all stocks
% Held by Institutions
32.61%vs all stocks
Total Cash (MRQ)
1.73BHKD221.13M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.47HKDUpdated Sep 26, 2026Total Debt (MRQ)
480.58MHKD61.26M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1370xvs Medical Devices peers
Current Ratio (MRQ)
4.67xvs Medical Devices peers
Book Value per Share (MRQ)
10.48HKDUpdated Sep 26, 2026Total Assets
3.45BCNY514.36M · vs all stocks (USD)
Total Current Assets
1.53BCNYFY2024 · Dec 31, 2024Total Liabilities
351.56MCNYFY2024 · Dec 31, 2024Total Non-current Assets
1.92BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
17.39MCNYFY2024 · Dec 31, 2024Total Current Liabilities
334.17MCNYFY2024 · Dec 31, 2024Cash
2.34BCNYFY2024 · Dec 31, 2024Cash Equivalents
-1.93BCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
418.11MCNYFY2024 · Dec 31, 2024Other Short-term Investments
864.78MCNYFY2024 · Dec 31, 2024Accounts Receivable
1.54MCNYFY2024 · Dec 31, 2024Inventory
205.48MCNYFY2024 · Dec 31, 2024Accounts Payable
69.37MCNYFY2024 · Dec 31, 2024Short-term Debt
89.40MCNYFY2024 · Dec 31, 2024Other Current Liabilities
2.66MCNYFY2024 · Dec 31, 2024Long-term Debt
1.50MCNYFY2024 · Dec 31, 2024Common Stock (Book)
330.18MCNYFY2024 · Dec 31, 2024Retained Earnings
65.28MCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
3.10BCNY461.99M · vs all stocks (USD)
Treasury Stock
100.70MCNYFY2024 · Dec 31, 202452-Week Low
17.10HKDUpdated Sep 26, 202652-Week High
28.00HKDUpdated Sep 26, 202652-Week Change
-7.61%vs all stocks
Beta
0.3070xvs all stocks
50-Day MA
20.23HKDUpdated Sep 26, 2026200-Day MA
21.76HKDUpdated Sep 26, 2026Avg 10-Day Volume
592.58KSharesUpdated Sep 26, 2026Avg 30-Day Volume
848.42KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
1.12HKDUpdated Sep 26, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Altman Z-Score 12.78: safe zoneNotable
Altman Z-Score: 12.78
High structural barrier to entryNotable
Barrier to Entry: 2.44
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking